Your browser doesn't support javascript.
loading
Secondary failure: immune responses to approved protein therapeutics.
Lagassé, H A Daniel; McCormick, Quinn; Sauna, Zuben E.
Afiliação
  • Lagassé HAD; Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration (FDA), Silver Spring, MD, USA.
  • McCormick Q; Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration (FDA), Silver Spring, MD, USA.
  • Sauna ZE; Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration (FDA), Silver Spring, MD, USA. Electronic address: zuben.sauna@fda.hhs.gov.
Trends Mol Med ; 27(11): 1074-1083, 2021 Nov.
Article em En | MEDLINE | ID: mdl-34493437
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Hemofilia A Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Hemofilia A Idioma: En Ano de publicação: 2021 Tipo de documento: Article